Combined expression of aldehyde dehydrogenase 1A1 and β-catenin is associated with lymph node metastasis and poor survival in breast cancer patients following cyclophosphamide treatment

Sun,Mingli; Zhao,Haishan; Xiao,Qinghuan; Yu,Zhaojin; Song,Zhiguo; Yao,Weifan; Tang,Hongtao; Guan,Shu; Jin,Feng; Wei,Minjie

doi:10.3892/or.2015.4273

Combined expression of aldehyde dehydrogenase 1A1 and β-catenin is associated with lymph node metastasis and poor survival in breast cancer patients following cyclophosphamide treatment

Authors:
- Mingli Sun
- Haishan Zhao
- Qinghuan Xiao
- Zhaojin Yu
- Zhiguo Song
- Weifan Yao
- Hongtao Tang
- Shu Guan
- Feng Jin
- Minjie Wei
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: September 15, 2015 https://doi.org/10.3892/or.2015.4273
Pages: 3163-3173

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated the expression of ALDH1A1 and β-catenin in breast cancer patients, and analyzed the correlation of their combined expression with clinicopathological features, chemotherapeutic responses, and prognosis of breast cancer patients. In total 276 human breast cancer tissues and 80 benign hyperplasia tissues were included. The expression of ALDH1A1 and β-catenin was examined using tissue microarray-based immunohistochemistry. ROC curve analysis was performed to determine an optimal cut-off score for the expression of ALDH1A1 and β-catenin, based on the survival status of breast cancer patients. Survival probabilities were estimated by the Kaplan-Meier method. ALDH1A1 expression was higher, but β-catenin showed no significant difference in breast cancer samples compared to controls. Compared with the membrane expression of β-catenin [β-catenin(m)], the cytoplasmic expression of β-catenin [β-catenin(c)] occurred significantly more frequently in breast cancer with the high expression of ALDH1A1 [ALDH1A1(high)] than in breast cancer with the low expression of ALDH1A1 [ALDH1A1(low)] (P=0.014). The expression level of ALDH1A was significantly higher in β-catenin(c) breast cancer than in β-catenin(m) breast cancer (P=0.020). ALDH1A1(high) expression or β-catenin(c) expression alone was associated with lymph node metastasis, and worse clinical outcome in breast cancer patients, especially in patients receiving cyclophosphamide treatment. Combined expression of ALDH1A1(high) and β-catenin(c) was associated with lymph node metastasis, poor outcome, and resistance to cyclophosphamide treatment. β-catenin may regulate ALDH1A1 expression in a subtype of breast cancer with ALDH1A1(high) and β-catenin(c) expression. ALDH1A1(high) and β-catenin(c) expression may be used as a biomarker for predicting poor prognosis in breast cancer following cyclophosphamide treatment.

View Figures

View References

1	Stebbing J and Ellis P: An overview of drug development for metastatic breast cancer. Br J Nurs. 21(Suppl 4): S18–S22. 2012. View Article : Google Scholar : PubMed/NCBI
2	Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sampieri K and Fodde R: Cancer stem cells and metastasis. Semin Cancer Biol. 22:187–193. 2012. View Article : Google Scholar : PubMed/NCBI
4	Neumeister V, Agarwal S, Bordeaux J, Camp RL and Rimm DL: In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 176:2131–2138. 2010. View Article : Google Scholar : PubMed/NCBI
5	Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
6	Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM: Cancer-initiating cell markers. Curr Mol Med. 8:784–804. 2008. View Article : Google Scholar : PubMed/NCBI
7	Nomura M, Fukuda T, Fujii K, Kawamura T, Tojo H, Kihara M, Bando Y, Gazdar AF, Tsuboi M, Oshiro H, et al: Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. J Clin Bioinforma. 1:232011. View Article : Google Scholar : PubMed/NCBI
8	Feng D, Wang N, Hu J and Li W: Surface markers of hepatocellular cancer stem cells and their clinical potential. Neoplasma. 61:505–513. 2014. View Article : Google Scholar : PubMed/NCBI
9	Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 13:2236–2252. 2009. View Article : Google Scholar
10	Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1:555–567. 2007. View Article : Google Scholar
11	Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, Zhang X, Cui YH, Bian XW and Yu SC: ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: A systematic review and meta-analysis. BMC Cancer. 14:4442014. View Article : Google Scholar : PubMed/NCBI
12	Wu S, Xue W, Huang X, Yu X, Luo M, Huang Y, Liu Y, Bi Z, Qiu X and Bai S: Distinct prognostic values of ALDH1 isoenzymes in breast cancer. Tumour Biol. 36:2421–2426. 2015. View Article : Google Scholar : PubMed/NCBI
13	Pandrangi SL, Chikati R, Chauhan PS, Kumar CS, Banarji A and Saxena S: Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells - an in vitro and in silico study. Tumour Biol. 35:723–737. 2014. View Article : Google Scholar
14	Sládek NE, Kollander R, Sreerama L and Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol. 49:309–321. 2002. View Article : Google Scholar
15	Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD and Matei D: β-catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene. 34:2297–2308. 2015. View Article : Google Scholar
16	Jiang W and Hiscox S: β-catenin - cell adhesion and beyond (Review). Int J Oncol. 11:635–641. 1997.PubMed/NCBI
17	Madjd Z, Gheytanchi E, Erfani E and Asadi-Lari M: Application of stem cells in targeted therapy of breast cancer: A systematic review. Asian Pac J Cancer Prev. 14:2789–2800. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lindvall C, Bu W, Williams BO and Li Y: Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev. 3:157–168. 2007. View Article : Google Scholar : PubMed/NCBI
19	Arend RC, Londoño-Joshi AI, Straughn JM Jr and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG and Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 97:4262–4266. 2000. View Article : Google Scholar : PubMed/NCBI
21	Yu Z, Xiao Q, Zhao L, Ren J, Bai X, Sun M, Wu H, Liu X, Song Z, Yan Y, et al: DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis. Mol Carcinog. Jan 25–2014.Epub ahead of print. View Article : Google Scholar
22	Fang Y, Wei J, Cao J, Zhao H, Liao B, Qiu S, Wang D, Luo J and Chen W: Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One. 8:e625582013. View Article : Google Scholar : PubMed/NCBI
23	Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, et al: Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesen-chymaltransition. Gut. 61:562–575. 2012. View Article : Google Scholar
24	Khoury T, Ademuyiwa FO, Chandrasekhar R, Jabbour M, Deleo A, Ferrone S, Wang Y and Wang X: Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol. 25:388–397. 2012. View Article : Google Scholar :
25	Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, et al: CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 16:1037–1047. 2012. View Article : Google Scholar : PubMed/NCBI
26	Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N and Yasui W: Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 62:112–119. 2012. View Article : Google Scholar : PubMed/NCBI
27	Avoranta ST, Korkeila EA, Ristamäki RH, Syrjänen KJ, Carpén OM, Pyrhönen SO and Sundström JT: ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer. Hum Pathol. 44:966–974. 2013. View Article : Google Scholar : PubMed/NCBI
28	Howe LR and Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther. 3:36–41. 2004. View Article : Google Scholar : PubMed/NCBI
29	López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL and O'Toole SA: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 19:301–309. 2010. View Article : Google Scholar : PubMed/NCBI
30	Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL and Rimm DL: Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 66:5487–5494. 2006. View Article : Google Scholar : PubMed/NCBI
31	Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R and Reis-Filho JS: β-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 24:209–231. 2011. View Article : Google Scholar
32	Wang S, Li W, Lv S, Wang Y, Liu Z, Zhang J, Liu T and Niu Y: Abnormal expression of Nek2 and β-catenin in breast carcinoma: Clinicopathological correlations. Histopathology. 59:631–642. 2011. View Article : Google Scholar : PubMed/NCBI
33	Barker N: The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol. 468:5–15. 2008. View Article : Google Scholar : PubMed/NCBI
34	Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, Arihiro K, Kataoka T, Okajima M and Asahara T: Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep. 14:1437–1443. 2005.PubMed/NCBI
35	Schlosshauer PW, Brown SA, Eisinger K, Yan Q, Guglielminetti ER, Parsons R, Ellenson LH and Kitajewski J: APC truncation and increased beta-catenin levels in a human breast cancer cell line. Carcinogenesis. 21:1453–1456. 2000. View Article : Google Scholar : PubMed/NCBI
36	Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, et al: Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. Stem Cells. 30:2366–2377. 2012. View Article : Google Scholar : PubMed/NCBI
37	Xu SL, Zeng DZ, Dong WG, Ding YQ, Rao J, Duan JJ, Liu Q, Yang J, Zhan N, Liu Y, et al: Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma. Int J Clin Exp Pathol. 7:2976–2986. 2014.PubMed/NCBI